remodeling of cardiovascular system and development of chronic kidney disease in patients with metabolic syndrome and obesity: role of genes enos, subunit p22-phox of nadph-oxidase and mthfr
Clicks: 249
ID: 140191
2012
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Popular Article
66.8
/100
249 views
199 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Aim. To examine contribution of polymorphisms of genes of endothelial NO-synthase (eNOS), NADPH-oxidase and methylenetetrahydrofolate reductase (mTHFR) to development of remodeling of cardiovascular system and chronic disease of the kidneys (CDK) in patients with metabolic syndrome (mS) and obesity. Material and methods. Standard clinical and device examinations were made and polymorphisms C242T of gene of subunit p22-phox of NADPH-oxidase, G894T of gene of eNOS and C677T of gene of MTHFR were studied in 66 MS patients (49 males and 17 females, age 19-62 years. Results. The presence of even one prognostically poor allele variants of the genes studied was registered in 83 examinees. The genotype 242TT p22-phox of NADPH-oxidase subunit was associated with the highest insulin resistance, allele 894T of gene eNOS - with reduced glomerular filtration rate and progression of left ventricular hypertrophy. Conclusion. Polymorphism of the genes the products of which modulate endothelial function can be considered as potential predictors of severity of MS target organs impairment.Reference Key |
saginova2012remodeling
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | ;E A Saginova;M G Gallyamov;A V Balatsky;A V Kolotvin;M V Severova;L M Samokhodskaya;V V Fomin;T N Krasnova;N A Mukhin |
Journal | indian journal of chemical technology |
Year | 2012 |
DOI | DOI not found |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.